Luminar Technologies에 대한 매도 수량은 투자자에게 Luminar Technologies의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Luminar Technologies (NASDAQ:LAZR) 주식, 공매도 수량 보고

Luminar Technologies

Luminar Technologies Inc is an automotive technology company ushering in a new era of vehicle safety and autonomy. It operates its business through the following segments: Autonomy Solutions and advanced Technologies and Services. The majority of revenue is earned from the Autonomy Solutions segment which engaged in the design, manufacturing, and sale of LiDAR sensors catering mainly to the OEMs in the automobile, commercial vehicle, robo-taxi, and adjacent industries and advanced Technologies and Services provides semiconductors and related components, as well as design, test and consulting services to the Autonomy Solutions segment and various third-party customers, including government agencies and defense contractors, in markets generally unrelated to autonomous vehicles.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

LAZR

SAVE

타이슨 푸드(NYSE:TSN)의 오늘 개장 전 분기 실적을 발표할 예정인데, 벤징가 프로의 데이터에 의하면 월가는 주당 39센트의 이익과 131.6억 달러의 매출을 나타낼 것으로 예상하고 다. 타이슨 푸드는 시간외 거래에서 0.1% 상승한 62.05달러에 거래됐다.

타이슨 푸드, 스피릿 항공 및 월요일에 주목해야 3개 주식

Luminar Technologies, Inc. - Class A Common Stock

Luminar Technologies Inc

Biotech

Guidance

Health Care

General

QNRX

Quoin Had Approximately $10.3M In Cash, Cash Equivalents And Marketable Securities As Of Sept. 30, 2024. This Is Expected To Fund The Company's Operations Into Late 2025

Standard BioTools Inc.&nbsp;("Standard BioTools" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAB#NASDAQ">LAB</a>) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools' finance organization.

Management

Standard BioTools Appoints Alex Kim As Chief Financial Officer, Effective November 11, 2024

OKLO

Oklo Says Department Of Energy And The Idaho National Laboratory Completed Environmental Compliance Process Addressing The DOE Requirements For Site Characterization At Fission Power Plant Site In Idaho

HC Wainwright &amp; Co. analyst Ed Arce reiterates Arbutus Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABUS#NASDAQ">ABUS</a>) with a Buy and maintains $5 price target.

Price Target

Reiteration

Analyst Ratings

ABUS

HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $5 Price Target

WK Kellogg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) reported quarterly sales of $689.000 which missed the analyst consensus estimate of $674.044 million by 100.00 percent. This is a 100.00 percent decrease over sales of $692.000 million the same period last year.

Earnings Misses

WK Kellogg Q3 Sales $689.000 Miss $674.044M Estimate

Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.46) by 2.17 percent.

Quoin Pharmaceuticals Q3 2024 GAAP EPS $(0.47) Misses $(0.46) Estimate

MBX Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBX#NASDAQ">MBX</a>) reported quarterly losses of $(2.78) per share. This is a 70.43 percent increase over losses of $(9.40) per share from the same period last year.

MBX Biosciences Q3 EPS $(2.78) Up From $(9.40) YoY

Jim Cramer expressed optimism about a resurgence in mergers and acquisitions (M&amp;A) with the incoming Trump administration. Cramer predicts a more lenient approach to M&amp;A approvals compared to the previous administration, which was known for its stringent antitrust scrutiny.
What Happened: Cramer highlighted that the regional banking sector could significantly benefit from increased M&amp;A activity, allowing banks to grow by acquiring smaller entities or merging to form larger &#8220;super regionals,&#8221; CNBC<a href="https://www.cnbc.com/2024/11/06/jim-cramer-market-for-mergers-and-acquisitions-is-back-under-trump.html"> reported</a> on Thursday.
"I am very confident in the idea that, under President Trump, M&amp;A's about to come back and come back bigly," he said. "Companies will no longer have to fear super-strict antitrust scrutiny, so long as they stay on the right side of our mercurial President elect."
He also suggested that antitrust regulations might be relaxed, potentially benefiting Big Tech companies that faced scrutiny under Biden&#8217;s appointees. However, Cramer warned that Trump&#8217;s personal views could still impact regulatory actions, referencing the 2017 attempt to block the AT&amp;T and Time Warner merger due to Trump&#8217;s issues with CNN.
Cramer noted that several prominent tech CEOs have publicly congratulated Trump, likely in anticipation of a more favorable regulatory environment.
See Also: <a href="https://www.benzinga.com/markets/equities/24/11/41763941/jim-cramer-blasts-super-micro-computers-earnings-better-at-exonerating-itself-than-selling-nvidi?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Jim Cramer Blasts Super Micro Computer&#8217;s Earnings: &#8216;Better At Exonerating Itself Than Selling&#8217; Nvidia GPUs</a>
Why It Matters: The potential revival of M&amp;A under Trump&#8217;s administration aligns with <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41798981/jim-cramer-calls-trumps-return-to-white-house-a-huge-win-for-the-stock-market">Cramer&#8217;s earlier remarks</a> that Trump&#8217;s return to the White House is a &#8220;huge win for the stock market.&#8221; The election of President-elect Trump has brought relief to traders, who anticipate pro-business policies, lower taxes, and deregulation. 
This optimism has already led to record highs in U.S. markets. The market rally <a href="https://www.benzinga.com/markets/asia/24/11/41801023/us-futures-european-stocks-rally-post-trump-victory-while-crude-oil-and-gold-decline-global-markets">post-Trump victory</a> saw the Dow, S&amp;P 500, and Nasdaq surge, with expectations of economic growth under Trump&#8217;s leadership. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41764063/dogecoin-powers-to-7-month-high-as-investors-anticipate-musk-headed-doge-department-under-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Dogecoin Powers To 7-Month High As Investors Anticipate Musk-Headed DOGE Department Under Trump</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Jim Cramer Hopes M&A To 'Come Back Bigly' Under Trump Administration

Oppenheimer analyst Jed Kelly upgrades Super Group (SGHC) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) from Perform to Outperform and announces $6 price target.

Upgrades

SGHC

Oppenheimer Upgrades Super Group (SGHC) to Outperform, Announces $6 Price Target

Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) reported quarterly losses of $(1.05) per share which beat the analyst consensus estimate of $(1.50) by 30 percent. This is a 94.44 percent decrease over losses of $(0.54) per share from the same period last year. The company reported quarterly sales of $16.352 million which beat the analyst consensus estimate of $12.609 million by 29.69 percent.

Earnings Beats

PHAT

Phathom Pharmaceuticals Q3 2024 Adj. EPS $(1.05) Beats $(1.50) Estimate, Sales $16.352M Beat $12.609M Estimate

2024 Financial Guidance
<ul>
<li>Maintained total net revenue guidance of $238 to $242 million, or 20% to 23% growth</li>
<li>Profitability guidance raised to 72% gross margin and 22% adjusted EBITDA margin, compared to the previous guidance of 71% and 21%, respectively</li>
</ul>

VCEL

Vericel Affirms FY24 Sales Guidance Of $238.00M-$242.00M Vs. $240.02M Estimate

LiveOne's Paid Members As Of September 30, 2024 Increased 645K Or 27%, As Compared To The Prior Year. Total Members Including Free Ad-supported Memberships Was Approximately 4M

Wheels Up Experience (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UP#NYSE">UP</a>) reported quarterly losses of $(0.08) per share. The company reported $193.90 million in sales this quarter. This is a 39.42 percent decrease over sales of $320.06 million the same period last year.

Wheels Up Experience Q3 EPS $(0.08) Up From $(3.15) YoY, Sales $193.90M Down From $320.06M YoY

Indaptus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces compelling safety, pharmacokinetics, and biomarker data on its lead compound, Decoy20, at the Society for Immunotherapy of Cancer (SITC) 2024 annual meeting. The data derive from two cohorts (13 patients) of Decoy20 single administration and one cohort (6 patients) of Decoy20 weekly administration in the Company's ongoing Phase 1 clinical trial. The SITC conference is being held November 6-10, 2024 in Houston, Tex.
The data presented demonstrated that Decoy20 administered intravenously once weekly mainly showed side effects that were classified as mild or moderate and transient in duration. Further, pharmacokinetic analysis confirmed that Decoy20 quickly disappeared from the bloodstream after administration, supporting the Company's "pulse" approach. One patient in the trial who has squamous cell carcinoma of the head and neck (SCCHN) with high levels of PD-L1, which is a protein that is associated with tumor response to certain immunotherapies, had "stable disease" — meaning the cancer had not progressed or worsened — at the time of their first imaging scan.

INDP

Indaptus Therapeutics Presents Encouraging Interim Safety Data From Phase 1 Clinical Trial Of Decoy20 At The Society For Immunotherapy Of Cancer 2024 Annual Meeting

WIIM

Texas Pacific Land shares are trading lower after the company reported a year-over-year decrease in Q3 EPS results and worse-than-expected Q3 sales results.

HC Wainwright &amp; Co. analyst Ed Arce reiterates Aligos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>) with a Buy and maintains $75 price target.

ALGS

HC Wainwright & Co. Reiterates Buy on Aligos Therapeutics, Maintains $75 Price Target

Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) reported quarterly earnings of $2.54 per share which beat the analyst consensus estimate of $2.41 by 5.39 percent. The company reported quarterly sales of $1.726 billion which beat the analyst consensus estimate of $1.677 billion by 2.90 percent. This is a 5.70 percent increase over sales of $1.633 billion the same period last year.

Ralph Lauren Q2 2025 Adj. EPS $2.54 Beats $2.41 Estimate, Sales $1.726B Beat $1.677B Estimate

LiveOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVO#NASDAQ">LVO</a>) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $(0.01) by 100 percent. This is a 77.78 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $32.59 million which missed the analyst consensus estimate of $33.70 million by 3.28 percent. This is a 14.25 percent increase over sales of $28.53 million the same period last year.

LiveOne Q2 2025 GAAP EPS $(0.02) Misses $(0.01) Estimate, Sales $32.59M Miss $33.70M Estimate

IHRT

iHeartMedia Q3 Sales $1.008B Beat $1.001B Estimate

Nano is Successfully Executing a Disciplined and Focused Value Creation Strategy to Drive Value for ALL Shareholders
Murchinson's Self-Serving Campaign is an Attempt to Take Control of Nano Through a Series of Proposals that Would Paralyze the Company's Strategy
Nano Urges Shareholders to Protect Their Investment and Vote "FOR" Nano's Proposals
Act Fast – Voting Cut-Off Sunday, December 1st, 2024, at 11:59 p.m. ET
To Learn More Visit: <a href="https://www.globenewswire.com/Tracker?data=gzWXWYPEmuxT_FDF7tP29TzULnkhGWfeFdtoFYVhazjDslpMj0ldHB5pPuUy0Z_Pefk22Phd7D3wBn129zu384B-e_DkBLlWduMae9P97tunW6AyM6YxQYY-NFv0tklJ">www.ProtectingNanoValue.com</a>
Waltham, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (NASDAQ:<a href="https://www.benzinga.com/stock/NNDM#NASDAQ">NNDM</a>) ("Nano" or the "Company"), a leading supplier of Additively Manufactured Electronics ("AME") and multi-dimensional polymer, metal &amp; ceramic Additive Manufacturing ("AM") 3D printing solutions, today sent a letter to its shareholders in connection with the Company's upcoming 2024 Annual General Meeting of Shareholders ("the Annual Meeting"). The letter reiterates the disciplined and focused steps the Company is taking to drive value for all shareholders.
&nbsp;

NNDM

Nano Dimension Sends Letter to Shareholders; Says Murchinson's Self-Serving Campaign Is An Attempt To Take Control Of Nano Through A Series Of Proposals That Would Paralyze The Company's Strategy; Nano Urges Shareholders To Protect Their Investment And Vote "FOR" Its Proposals

Luminar: Darkest Before The Dawn

Luminar's Revenue Delays, Debt Renegotiations, And Looming Equity Dilution

Ouster: Another Market Overreaction

Ouster Q2: Why The Selloff Doesn't Add Up And Why $23 Per Share Remains A Target

LiDAR Quarterly Insights Q2 2024 Summary

Mobileye: Bright Future, But Intel Overhang Is A Problem

Luminar Technologies announces workforce reduction

LiDAR Battle: US Proposals Strengthen Ouster But Leave Consumer Sectors Exposed To Chinese Competition

Luminar: Balance Sheet And Competition Concerns Overwhelm Potential Upside

Top 10 most shorted stocks on Wall Street

AEVA

BLNK

BLUE

CPTN

HSAI

INVZ

KSCP

LIDR

MBLY

MVIS

NKLA

OUST

SEDG

SPCE

WOLF

Press Releases

Luminar Reports First Quarter 2024 Business Update and Financials

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Luminar Technologies, Inc. (NASDAQ: LAZR)

Luminar Launches Sentinel Software for Automakers

Luminar to Provide Q2'24 Business Update on August 6, 2024

Luminar Bolsters Balance Sheet & Reports Second Quarter 2024 Business Update

BestGrowthStocks.Com Issues a Comprehensive Analysis of Luminar Technologies and Proposed Trade Restrictions

LAZR, LGMK, RIME, REGRF: Leaders Report Latest Advances in AI Transformation, Rolex Watch Market, LiDAR, and HealthTech for Aging

Leaders in The News: BigBear.ai, Luminar, New World Solutions, Tevogen Bio

Luminar to Provide Q3'24 Business Update November 11th; Reminder for Stockholders Meeting October 30th

BBAI

CSE:NEWS

LGMK

REGRF

RIME

TVGN

Adient

Autoliv

Aptiv

American Axle & Manufacturing Holdings, Inc. Common Stock

American Axle & Mfg Hldgs

BorgWarner

Dana

Dorman Prods

ECARX Holdings Inc. - Class A Ordinary shares

ECARX Holdings

Fox Factory Hldg

Gentex

Garrett Motion

Holley

Hesai Group - American Depositary Share, each ADS represents one Class B ordinary share

Comments

Luminar Technologies

매도 수량

Luminar Technologies (NASDAQ:LAZR) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌